|
Jul 4
|
Novartis’ Cosentyx shows no benefit in Phase III GCA trial
|
|
Jul 3
|
Switzerland seeks trade deal with Trump without getting into EU bind
|
|
Jul 3
|
Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study
|
|
Jul 3
|
FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
|
|
Jul 3
|
Business and Investment Opportunities in Nuclear Medicine 2025-2030: North America Leads, Asia-Pacific Races
|
|
Jul 3
|
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
|
|
Jul 3
|
Actinium Highlights ATNM 400 Progress at SNMMI Conference
|
|
Jul 2
|
Buy These 5 Low-Leverage Stocks Amid Wall Street's Tricky July Start
|
|
Jul 2
|
What's Fueling Tempus AI's Explosive Sales Growth?
|
|
Jul 2
|
Can China sustain a surge in oncology drug innovation?
|
|
Jul 1
|
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
|
|
Jul 1
|
Novartis AG (NVS) Hits Fresh High: Is There Still Room to Run?
|
|
Jun 28
|
Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion
|
|
Jun 27
|
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
|
|
Jun 26
|
Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?
|
|
Jun 26
|
Incyte replaces CEO Hoppenot with dealmaker Meury
|
|
Jun 26
|
Kashiv BioSciences reports positive results from trial of Xolair biosimilar
|
|
Jun 26
|
ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease
|
|
Jun 26
|
Retinitis Pigmentosa Research Report 2025: $25+ Bn Market Opportunities and Strategies to 2034 - Gene Therapy Poised as Fastest Growing Treatment Segment, Strategic Collaborations Drive Advancements
|
|
Jun 26
|
Novartis concludes Regulus Therapeutics acquisition
|